Permira is selling Australia's I-Med Radiology Network, which recently entered the U.S. by acquiring StatRad, to Hong Kong-based multinational conglomerate Jardine Matheson.
The Bedford, Massachusetts-based company has reportedly been approached about a possible acquisition by competitor Curium Pharma, Bloomberg reported May 22.
Last week hospitals owned by three big health systems filed suit against CVS Health. The trio filed separately, but all accuse the corporation of robbing them of funds they’re owed through the federal 340B drug pricing program.
The change would represent an imperfect but, in many cases, perfectly appropriate way to oversee the technology without crimping its capabilities. So say three thought leaders who are close watchers of medical ethics and technologies.
The intrusion was caused by the compromised credentials of a Hartford HealthCare employee. Data stolen included full names, Medicaid ID numbers and patient treatment details.
Duke Health said the analytics platform will help it better understand the patient care needs of the local community, improve satisfaction scores and guide decisions about expanding services.
Elisabeth Potter, MD, said her clinic has been removed from the insurer’s provider networks, putting her business $5 million in debt as she faces a lawsuit over a social media video.
The excessive use of electronic devices is associated with significant health risks for young children and adolescents. In fact, too much screen time may impact the body in ways that last well into adulthood.
The U.S. Department of Justice confirmed that divestitures will be made in 19 of the 20 states at high risk of overconsolidation in the hospice market as a result of the merger. The transaction is now expected to move forward.
Permira is selling Australia's I-Med Radiology Network, which recently entered the U.S. by acquiring StatRad, to Hong Kong-based multinational conglomerate Jardine Matheson.
The Bedford, Massachusetts-based company has reportedly been approached about a possible acquisition by competitor Curium Pharma, Bloomberg reported May 22.
